Zimmer Biomet Holdings Inc
- 取引所
- 米国株
- 国 / 地域
- USA
- 上場日
- 2001年7月25日
- 従業員数
- 17,000
- 公式サイト
- www.zimmerbiomet.com
総合バリュエーションレンジ · 保守的 $70–$80 / 妥当 $95–$110 / 楽観的 $125–$145。$92.07 時点で 保守的レンジと妥当レンジの間。
レポート公開時 $82.33（2026年5月30日）
データ提供：EODHD、報告通貨で表示。参考情報であり、投資助言ではありません。
Zimmer Biomet Holdings, Inc., together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, upper extremities, and trauma and CMFT products; sports medicine products for the repair of soft tissue injuries, used in the knee and shoulder; and craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open-heart surgery, trauma, or for deformities of the chest. It offers technology and data, bone cement, and surgical products; and a suite of integrated digital and robotic technologies that leverage data, data analytics and artificial intelligence. The company's products and solutions are used to treat patients suffering from disorders of, or injuries to, bones, joints, or supporting soft tissues. It serves orthopedic surgeons, neurosurgeons, hospitals, healthcare institutions, stocking distributors, healthcare dealers, and other specialists, as well as agents, healthcare purchasing organizations, or buying groups. It also offers ROSA Robot, which utilizes robotic technologies to assist a surgeon with implant positioning in total knee arthroplasty or partial knee arthroplasty; and the ZBEdge Platform connects robotic and digital technologies together to collect data before, during and after surgery, that can deliver insights to surgeons to assist in making informed decisions on patient care. The company was formerly known as Zimmer Holdings, Inc. and changed its name to Zimmer Biomet Holdings, Inc. in June 2015. Zimmer Biomet Holdings, Inc. was founded in 1927 and is headquartered in Warsaw, Indiana.
沿革
Zimmer Biomet Holdings, Inc. was founded in 1927 and is headquartered in Warsaw, Indiana. The company went public on July 25, 2001, and was formerly known as Zimmer Holdings, Inc. before changing its name to Zimmer Biomet Holdings, Inc. in June 2015. It has grown into a global medical technology platform with roughly 17,000 employees, generating $8.232 billion in revenue and $1.697 billion in operating cash flow in 2025. The company has relied heavily on acquisitions to broaden its portfolio and accelerate growth: in 2025 it completed the Paragon 28 acquisition for total consideration of about $1.2765 billion and the Monogram acquisition for total consideration of about $0.3775 billion, and it has used deals such as Paragon 28, Monogram, and OrthoGrid to build out higher-growth areas like foot and ankle and robotics. Effective May 29, 2025, Ivan Tornos serves as Chairman, President, and CEO, with the board also appointing a Lead Independent Director.
業界での地位
Zimmer Biomet is a global orthopedic implant maker operating in more than 25 countries and selling products in more than 100 countries. Its 2025 revenue of $8.232 billion came from four product clusters: knee at $3.322 billion, hip at $2.094 billion, S.E.T. at $2.150 billion, and Technology & Data, bone cement, and surgical solutions at $0.666 billion. Disclosed knee brands include Persona, NexGen, Vanguard, and Oxford; hip brands include Taperloc, Avenir Complete, Z1, Arcos, and G7; its robotic platform is ROSA and its digital platform is ZBEdge, which collects data before, during, and after surgery. Among orthopedic peers, 2025 figures place Stryker's Orthopaedics business at about $9.5 billion, Johnson & Johnson's Orthopaedics business at about $9.2 billion (2024), and Smith+Nephew group revenue at about $6.164 billion, against Zimmer Biomet's $8.232 billion, giving it a high but not dominant position. The company defines its competitive factors as technology, innovation, quality, reputation, customer service, and price. Its competitive advantages stem from scale and global distribution, surgeon proficiency and hospital instrument systems, consignment inventory and intra-operative workflow that raise switching costs, FDA 510(k) and quality-system regulatory barriers, and a portfolio of more than 6,000 issued patents and patent applications. The company has comparatively weak network effects and limited data advantage, and acknowledges competitors may hold stronger resources, faster technology response, more aggressive pricing, and more effective channel coverage.
この銘柄のレポートはお使いの言語でまだありません。